Page 9 - Resure Sealant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resure sealant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resure Sealant Today - Breaking & Trending Today

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Antony Mattessich , Watts Water Technologies Inc , Company Board Of Directors , Bowdoin College , Ocular Therapeutix Inc , Exchange Commission , Laboratories Inc , Excelitas Technologies Corporation , University Of Chicago , Company Executive Vice , Board Of Directors Transmedics Group Inc , Merilee Raines , Chief Executive Officer , Executive Vice President , Chief Financial Officer , Transmedics Group , Watts Water Technologies , Certified Public Accountant , Ocular Therapeutix , Prescription Drug User Fee Act , Resure Sealant , Private Securities Litigation Reform Act , வாட்ஸ் தண்ணீர் தொழில்நுட்பங்கள் இன்க் , நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் , பெடோய்ன் கல்லூரி , பரிமாற்றம் தரகு ,

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , South Korea , Scott Corning , Rabia Gurses Ozden , Antony Mattessich , Donald Notman , Michael Goldstein , Chris Brinzey , Regeneron Pharmaceuticals , Drug Administration , Key Program Updates , Horizons Forum , Ocular Therapeutix Inc , Exchange Commission , American Medical Association , Clinical Development , Chief Executive , Interim Data , Wet Age Related Macular Degeneration , Primary Open Angle Glaucoma , Ocular Hypertension , Annual Glaucoma , First Patient , Trial Evaluating , Procedure Terminology , New Drug Application ,

Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Published: Mar 01, 2021
Ocular Therapeutix
™
Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

BEDFORD, Mass. (BUSINESS WIRE) Ocular Therapeutix ™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patient in its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the signs and symptoms of dry eye disease.
“We are excited to have recently begun dosing patients in the Phase 2 clinical trial of OTX-DED,” said Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer. “Many dry eye patients experience episodic flares of their signs and symptoms related primarily to inflammation. Topical steroi ....

Michael Goldstein , Regeneron Pharmaceuticals , Exchange Commission , Ocular Therapeutix Inc , Chief Medical , Market Scope , Ocular Therapeutix , Private Securities Litigation Reform Act , Resure Sealant , Ocular Therapeutix Announces First Patient Dosed In Phase 2 Clinical Trial Of Otx Ded For The Short Term Treatment Signs And Symptoms Dry Eye Disease , மைக்கேல் கோல்ட்ஸ்டைன் , பரிமாற்றம் தரகு , தலைமை மருத்துவ , சந்தை வாய்ப்பு , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development

Published: Jan 07, 2021
BEDFORD, Mass. (BUSINESS WIRE) Ocular Therapeutix , Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be responsible for clinical operations and in that capacity will maintain his role as Chief Medical Officer. He will also be responsible for commercial operations in alignment with the overall Company strategy. The Company also announced the appointment of Rabia Gurses Ozden, MD, as Senior Vice President (SVP), Clinical Development. As SVP, Clinical Development, Dr. Ozden is responsible for leading the clinical development of Ocular Therapeutix’s current and ....

New York , United States , Antony Mattessich , Michael Goldstein , Carl Zeiss Meditec , Genetic Technologies Corporation , Regeneron Pharmaceuticals , Bausch Lomb Pharmaceuticals , Ocular Therapeutix Inc , Exchange Commission , Ankara University School Of Medicine , Hacettepe University School Of Medicine , Akouos Inc , Quark Pharmaceuticals , Ocular Therapeutix , Chief Executive Officer , Chief Medical Officer , Chief Development Officer , Nightstar Therapeutics , Applied Genetic Technologies Corporation , Lomb Pharmaceuticals , Hacettepe University School , Ankara University School , New York Eye , Private Securities Litigation Reform Act , Resure Sealant ,